Sex as a Biological Variable Supplement - Drug repurposing for the rapid development and evaluation of SARS-CoV-2 antivirals

  • Funded by Canadian Institutes of Health Research (CIHR)
  • Total publications:0 publications

Grant number: Supplement to P00182

Grant search

Key facts

  • Disease

  • Start & end year

  • Known Financial Commitments (USD)

  • Funder

    Canadian Institutes of Health Research (CIHR)
  • Principle Investigator

  • Research Location

    Canada, Americas
  • Lead Research Institution

    University of Ottawa
  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags


  • Study Subject


  • Clinical Trial Details


  • Broad Policy Alignment


  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable


The initial symptoms of COVID-19 are fever, shortness of breath and a dry cough. For some patients, the disease progresses to pneumonia as the infection spreads to the lung and leads severe inflammation. These severe symptoms can cause difficulties for the lungs to oxygenate the blood and can lead to death. There are currently no antivirals against SARS-CoV2, the causative agent of COVID-19, and development of new molecules can take years to reach patients. As the COVID-19 epidemic is progressing rapidly, the need for antiviral therapy is urgent. Therefore, our goal is to use our current arsenal of approved drugs already tested for their safety and used in the clinic for various conditions and repurpose them to treat COVID-19. In this rapid response grant, we propose to identify drugs with activity against SARS-CoV2 in vitro and in vivo and contribute to the global COVID-19 response and provide a therapeutic option for patients developing life-threatening disease.